1. Cytokine-induced killer cells promote antitumor immunity
- Author
-
Changping Wu, Jingting Jiang, and Binfeng Lu
- Subjects
Adoptive cell transfer ,Review ,Mice, SCID ,Biology ,General Biochemistry, Genetics and Molecular Biology ,Cell therapy ,Mice ,03 medical and health sciences ,Interleukin 21 ,Cytokine-Induced Killer Cells ,Lymphocytes, Tumor-Infiltrating ,0302 clinical medicine ,Cell Line, Tumor ,Neoplasms ,Biomarkers, Tumor ,Animals ,Humans ,Cytotoxic T cell ,Medicine(all) ,Lymphokine-activated killer cell ,Cytokine-induced killer cell ,Biochemistry, Genetics and Molecular Biology(all) ,Tumor-infiltrating lymphocytes ,General Medicine ,3. Good health ,030220 oncology & carcinogenesis ,Immunology ,Blood Component Removal ,Leukocytes, Mononuclear ,Interleukin 12 ,Cytokines ,Immunotherapy ,030215 immunology - Abstract
The number of immune cells, especially dendritic cells and cytotoxic tumor infiltrating lymphocytes (TIL), particularly Th1 cells, CD8 T cells, and NK cells is associated with increased survival of cancer patients. Such antitumor cellular immune responses can be greatly enhanced by adoptive transfer of activated type 1 lymphocytes. Recently, adoptive cell therapy based on infusion of ex vivo expanded TILs has achieved substantial clinical success. Cytokine-induced killer (CIK) cells are a heterogeneous population of effector CD8 T cells with diverse TCR specificities, possessing non-MHC-restricted cytolytic activities against tumor cells. Preclinical studies of CIK cells in murine tumor models demonstrate significant antitumor effects against a number of hematopoietic and solid tumors. Clinical studies have confirmed benefit and safety of CIK cell-based therapy for patients with comparable malignancies. Enhancing the potency and specificity of CIK therapy via immunological and genetic engineering approaches and identifying robust biomarkers of response will significantly improve this therapy.
- Published
- 2013